Company intelligence / Profile preview
Biomica
Rehovot, Central District / N/A, Israelbiomicamed.com ↗
- Ownership
- Public · EVGN
- Development stage
- Phase 1
01
Overview
Biomica develops innovative microbiome-based therapeutics using its proprietary PRISM platform, focusing on cancer, immune-mediated, and infectious diseases. The company leverages big data and AI to identify functional elements of the human microbiome for targeted therapy development. Recent financing rounds have supported advancement of its pipeline
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Microbiome-based therapeutics (live bacterial consortia)
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
Engaged in strategic partnerships via events like the Microbiome Times Partnering Forum; specific partners not named publicly as of latest updates
Beyond the preview
Go deeper on Biomica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biomica.